Crown Laboratories Acquires Revance Therapeutics, Expanding Aesthetic Portfolio
The deal expands Crown’s presence in the aesthetics market, bringing Daxxify and the RHA Collection into its portfolio.
The deal expands Crown’s presence in the aesthetics market, bringing Daxxify and the RHA Collection into its portfolio.
The phase IV trial evaluated outcomes of Sculptra plus Restylane Lyft or Contour in patients with facial volume loss due to weight loss medications.